2024 Wells Fargo Healthcare Conference
Logotype for PROCEPT BioRobotics Corporation

PROCEPT BioRobotics (PRCT) 2024 Wells Fargo Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for PROCEPT BioRobotics Corporation

2024 Wells Fargo Healthcare Conference summary

22 Jan, 2026

HYDROS system launch and features

  • HYDROS, the next-generation robotic system, introduces AI Assist for assisted planning, improving surgical outcomes by reducing variability in treatment planning.

  • Workflow is streamlined, making setup easier and reducing reliance on specialist staff, addressing prior inefficiencies.

  • Enhanced imaging with improved ultrasound and a digital cystoscope simplifies the physician experience.

  • HYDROS is designed for mass market adoption, making it more accessible and appealing to a broader range of hospitals and surgeons.

  • The system is expected to accelerate patient flow and increase surgeon adoption within hospitals.

Commercial strategy and financial outlook

  • Initial HYDROS commercialization focuses on greenfield opportunities, with reps not incentivized to sell replacements in Q3 and Q4.

  • Average selling price (ASP) for HYDROS is guided at $380,000 for the back half of the year, with potential upside in 2025.

  • Margins are expected to remain stable, as HYDROS costs are comparable to AquaBeam, and higher ASPs are anticipated.

  • ROI for hospitals is expected to remain attractive, with potential for increased throughput and multisystem orders.

  • Some sales disruption is expected in Q3 due to rep training, but the transition should be complete by the end of 2024.

Market expansion and adoption

  • Near-term strategy remains focused on cannibalizing TURP and GreenLight procedures, with only 10% market share in resective surgery as of 2024.

  • HYDROS is expected to make the system more appealing to low and medium-volume hospitals, expanding the addressable market.

  • The company is piloting entry into the ASC setting, aiming for market expansion rather than shifting existing hospital procedures.

  • Same-day discharge rates are increasing, with 20-30% of patients discharged the same day, and some surgeons achieving over 90%.

  • Utilization growth is a key focus, with significant room to increase procedures per system and expand within existing accounts.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more